Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long Term Efficacy of Faricimab Using a Treat and Extend Regimen for Type 3 Macular Neovascularization

NCT07187804 is registered in ClinicalTrials.gov with Kim's Eye Hospital as lead sponsor.

NCT NCT07187804
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07187804 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long Term Efficacy of Faricimab Using a Treat and Extend Regimen for Type 3 Macular Neovascularization
Lead sponsor
Kim's Eye Hospital
Phase
Phase 4
Overall status
Not yet recruiting
Start date
September 23, 2025
Completion date
September 22, 2028
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

age-related macular degeneration (armd), anti-vascular endothelial growth factor, choroidal neovascularization